Detects human IL‑1ra/IL-1F3 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse IL‑1ra/IL‑1F3, recombinant rat IL-1ra/IL-1F3, recombinant porcine IL‑1ra/IL-1F3, and recombinant equine IL‑1ra/IL-1F3 is observed, and less than 1% cross-reactivity with recombinant human (rh) IL-1a, rhIL-1b, rhIL-18, and rhIL-1H1 is observed.
Polyclonal Goat IgG
Protein A or G purified
E. coli-derived recombinant human IL‑1ra/IL-1F3 Arg26-Glu177 Accession # P18510
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Human IL‑1ra/IL‑1F3 (Catalog # 280-RA)
Measured by its ability to neutralize IL‑1ra/IL‑1F3 inhibition of IL‑1 alpha /IL‑1F1-dependent proliferation in the D10.G4.1 mouse helper T cell line [Symons, J.A. et al. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 272]. The Neutralization Dose (ND50) is typically 5-10 µg/mL in the presence of 50 ng/mL Recombinant Human IL‑1ra/IL‑1F3, 50 pg/mL Recombinant Human IL‑1 alpha /IL‑1F1 and 1.25 µg/mL concanavalin A.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
IL‑1ra/IL‑1F3 Inhibition of IL‑1 alpha /IL‑1F1-dependent Cell Proliferation and Neutralization by Human IL‑1ra/IL‑1F3 Antibody. Recombinant Human IL‑1ra/IL‑1F3 (Catalog # 280‑RA) inhibits Recombinant Human IL‑1 alpha /IL‑1F1 (Catalog # 200-LA) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL‑1 alpha /IL‑1F1 (50 pg/mL) activity elicited by Recombinant Human IL‑1ra/IL‑1F3 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑1ra/IL‑1F3 Polyclonal Antibody (Catalog # AB-280-NA). The ND50 is typically 5-10 µg/mL in the presence of concanavalin A (1.25 µg/mL).
Preparation and Storage
Reconstitute at 1 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha. It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells, but reportedly will not block binding to the type II receptor on murine pre-B cell lines. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. Currently, pre-clinical and clinical studies are underway to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.